|
1
|
Louis DN, Perry A, Reifenberger G, von
Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD,
Kleihues P and Ellison DW: The 2016 World Health Organization
Classification of Tumors of the Central Nervous System: A summary.
Acta Neuropathol. 131:803–820. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Omuro A and DeAngelis LM: Glioblastoma and
other malignant gliomas: A clinical review. JAMA. 310:1842–1850.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Alifieris C and Trafalis DT: Glioblastoma
multiforme: Pathogenesis and treatment. Pharmacol Ther. 152:63–82.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Anjum K, Shagufta BI, Abbas SQ, Patel S,
Khan I, Shah SAA, Akhter N and Hassan SSU: Current status and
future therapeutic perspectives of glioblastoma multiforme (GBM)
therapy: A review. Biomed Pharmacother. 92:681–689. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Aldape K, Zadeh G, Mansouri S,
Reifenberger G and von Deimling A: Glioblastoma: Pathology,
molecular mechanisms and markers. Acta Neuropathol. 129:829–848.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Network TC: Corrigendum: Comprehensive
genomic characterization defines human glioblastoma genes and core
pathways. Nature. 494:5062013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Vanhaesebroeck B, Guillermet-Guibert J,
Graupera M and Bilanges B: The emerging mechanisms of
isoform-specific PI3K signalling. Nat Rev Mol Cell Biol.
11:329–341. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Brennan CW, Verhaak RG, McKenna A, Campos
B, Noushmehr H, Salama SR, Zheng S, Chakravarty D, Sanborn JZ,
Berman SH, et al: ; TCGA Research Network: The somatic genomic
landscape of glioblastoma. Cell. 155:462–477. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Avivar-Valderas A, McEwen R,
Taheri-Ghahfarokhi A, Carnevalli LS, Hardaker EL, Maresca M, Hudson
K, Harrington EA and Cruzalegui F: Functional significance of
co-ocπcurring mutations in PIK3CA and MAP3K1 in breast cancer.
Oncotarget. 9:21444–21458. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
García-Escudero R, Segrelles C, Dueñas M,
Pombo M, Ballestín C, Alonso-Riaño M, Nenclares P,
Álvarez-Rodríguez R, Sánchez-Aniceto G, Ruíz-Alonso A, et al:
Overexpression of PIK3CA in head and neck squamous cell carcinoma
is associated with poor outcome and activation of the YAP pathway.
Oral Oncol. 79:55–63. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Peyre M, Gaillard S, de Marcellus C, Giry
M, Bielle F, Villa C, Boch AL, Loiseau H, Baussart B, Cazabat L, et
al: Progestin-associated shift of meningioma mutational landscape.
Ann Oncol. 29:681–686. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Schwartz S, Wongvipat J, Trigwell CB,
Hancox U, Carver BS, Rodrik-Outmezguine V, Will M, Yellen P, de
Stanchina E, Baselga J, et al: Feedback suppression of PI3Kα
signaling in PTEN-mutated tumors is relieved by selective
inhibition of PI3Kβ. Cancer Cell. 27:109–122. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yuzugullu H, Baitsch L, Von T, Steiner A,
Tong H, Ni J, Clayton LK, Bronson R, Roberts TM, Gritsman K, et al:
A PI3K p110β-Rac signalling loop mediates Pten-loss-induced
perturbation of haematopoiesis and leukaemogenesis. Nat Commun.
6:85012015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wee S, Wiederschain D, Maira SM, Loo A,
Miller C, deBeaumont R, Stegmeier F, Yao YM and Lengauer C:
PTEN-deficient cancers depend on PIK3CB. Proc Natl Acad Sci USA.
105:13057–13062. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ni J, Liu Q, Xie S, Carlson C, Von T,
Vogel K, Riddle S, Benes C, Eck M, Roberts T, et al: Functional
characterization of an isoform-selective inhibitor of PI3K-p110β as
a potential anticancer agent. Cancer Discov. 2:425–433. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gao J, Aksoy BA, Dogrusoz U, Dresdner G,
Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, et al:
Integrative analysis of complex cancer genomics and clinical
profiles using the cBioPortal. Sci Signal. 6:pl12013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Cerami E, Gao J, Dogrusoz U, Gross BE,
Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, et
al: The cBio cancer genomics portal: An open platform for exploring
multidimensional cancer genomics data. Cancer Discov. 2:401–404.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Gu Z, Eils R and Schlesner M: Complex
heatmaps reveal patterns and correlations in multidimensional
genomic data. Bioinformatics. 32:2847–2849. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yang W, Soares J, Greninger P, Edelman EJ,
Lightfoot H, Forbes S, Bindal N, Beare D, Smith JA, Thompson IR, et
al: Genomics of Drug Sensitivity in Cancer (GDSC): A resource for
therapeutic biomarker discovery in cancer cells. Nucleic Acids Res.
41:D955–D961. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Laco F, Woo TL, Zhong Q, Szmyd R, Ting S,
Khan FJ, Chai CLL, Reuveny S, Chen A and Oh S: Unraveling the
inconsistencies of cardiac differentiation efficiency induced by
the GSK3β inhibitor CHIR99021 in human pluripotent stem cells. Stem
Cell Reports. 10:pp. 1851–1866. 2018, View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Liu SL, Liu Z, Zhang LD, Zhu HQ, Guo JH,
Zhao M, Wu YL, Liu F and Gao FH: GSK3β-dependent cyclin D1 and
cyclin E1 degradation is indispensable for NVP-BEZ235 induced G0/G1
arrest in neuroblastoma cells. Cell Cycle. 16:2386–2395. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang J, Li XM, Bai Z, Chi BX, Wei Y and
Chen X: Curcumol induces cell cycle arrest in colon cancer cells
via reactive oxygen species and Akt/GSK3β/cyclin D1 pathway. J
Ethnopharmacol. 210:1–9. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lien EC, Dibble CC and Toker A: PI3K
signaling in cancer: Beyond AKT. Curr Opin Cell Biol. 45:62–71.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Fruman DA, Chiu H, Hopkins BD, Bagrodia S,
Cantley LC and Abraham RT: The PI3K pathway in human disease. Cell.
170:605–635. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Jia S, Liu Z, Zhang S, Liu P, Zhang L, Lee
SH, Zhang J, Signoretti S, Loda M, Roberts TM, et al: Corrigendum:
Essential roles of PI(3)K-p110β in cell growth, metabolism and
tumorigenesis. Nature. 533:2782016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chen H, Mei L, Zhou L, Shen X, Guo C,
Zheng Y, Zhu H, Zhu Y and Huang L: PTEN restoration and PIK3CB
knockdown synergistically suppress glioblastoma growth in vitro and
in xenografts. J Neurooncol. 104:155–167. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Mikheev AM, Mikheeva SA, Severs LJ, Funk
CC, Huang L, McFaline-Figueroa JL, Schwensen J, Trapnell C, Price
ND, Wong S, et al: Targeting TWIST1 through loss of function
inhibits tumorigenicity of human glioblastoma. Mol Oncol.
12:1188–1202. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Verreault M, Weppler SA, Stegeman A,
Warburton C, Strutt D, Masin D and Bally MB: Combined RNAi-mediated
suppression of Rictor and EGFR resulted in complete tumor
regression in an orthotopic glioblastoma tumor model. PLoS One.
8:e595972013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Malumbres M and Barbacid M: Cell cycle,
CDKs and cancer: A changing paradigm. Nat Rev Cancer. 9:153–166.
2009. View
Article : Google Scholar : PubMed/NCBI
|
|
30
|
Fedorov SN, Shubina LK, Bode AM, Stonik VA
and Dong Z: Dactylone inhibits epidermal growth factor-induced
transformation and phenotype expression of human cancer cells and
induces G1-S arrest and apoptosis. Cancer Res. 67:5914–5920. 2007.
View Article : Google Scholar : PubMed/NCBI
|
